Making the UK the best milieu for delivering medical innovations using in silico evidence and regulatory science.

A well-integrated and cohesive community can deliver a national strategy that accelerates the adoption of in silico trials and supports its uptake by the UK’s LifeSciences sector.

The strategy must be adapted to the specific challenges, drivers, and opportunities in the UK, and engage with international initiatives to achieve faster, safer, and more cost-effective innovation for patient benefit.

In silico trials

refers to the development of patient-specific models and simulations to form virtual cohorts for assessing the safety and/or efficacy of new drugs and new medical devices.

In silico, in vitro, in vivo, in situ…

Complementary sources of scientific evidence and drive confidence in patient benefit, safety, and effectiveness

In silico medicine

or computational medicine, is an emerging discipline devoted to quantitative approaches for understanding the mechanisms, diagnosis, and treatment of human disease through the systematic application of mathematics, engineering, and computational science.

1n Silico Trials: Market Size & Areas of Early Adoption in Medical Product Innovation & Regulation

Contribute to our study by responding to this brief survey

Driving UK innovation, policy, and regulation in life sciences and healthtech for patient benefit

A community driving innovation and growth for patient safety and benefit using in silico evidence and regulatory science

"The TIGRR Report recommends the Prime Minister how the UK can reshape its approach to regulation and seize new opportunities from Brexit with its newfound regulatory freedoms."

Rt Hon Sir Iain Duncan Smith MP, the Rt Hon Theresa Villiers MP, and George Freeman MP, The Taskforce on Innovation, Growth and Regulatory Reform

“We will use the provisions of the Medicines and Medical Devices Act 2021 to overhaul our clinical trial frameworks, giving a major boost to the UK’s world-class R&D sector and get patients access to new lifesaving medicines more quickly.”

A community effort

Coordinated by InnovateUK KTN and the Royal Academy of Engineering, in collaboration with Avicenna Alliance and the Virtual Human Physiological Institute, we work with trade organisations, regulators, standardisation bodies and UK government.

We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.

Created with
Mailchimp Freddie Badge
Twitter icon
LinkedIn icon
Website icon
Email icon

© 2022-2023 InSilicoUK Network